Logo on white.png
EsoCap and Upadia sign exclusive licensing agreement combining EsoCap technology with Upadia antibodies for the treatment of Barrett’s esophagus
January 10, 2022 05:32 ET | EsoCap AG
Licensing deal grants EsoCap exclusive access to Upadia’s monoclonal antibodies for a local therapy for Barrett’s esophagusBarrett’s esophagus, a disease of the esophagus with high unmet medical need,...
FStar.jpg
F-star Therapeutics Announces Merck KGaA, Darmstadt, Germany Exercises a Fourth Licensing Option in Immuno-Oncology Collaboration
January 05, 2022 08:00 ET | F-star Therapeutics, Inc.
CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next...
Arbutus Biopharma Logo
Arbutus and Qilu Pharmaceutical Enter into an Exclusive Licensing Agreement and Strategic Partnership to Develop and Commercialize AB-729 in mainland China, Hong Kong, Macau and Taiwan
December 13, 2021 07:30 ET | Arbutus Biopharma Corporation
Qilu Pharmaceutical, one of the leading pharmaceutical companies in China, becomes strategic partner to provide development, manufacturing and commercialization expertise for the mainland China, Hong...
LOGO.png
GCANRx Signs Licensing Agreement with Shaare Zedek Scientific for Innovative Neuropsychiatric Cannabinoid Therapy
August 19, 2021 09:45 ET | The Greater Cannabis Company, Inc.
BALTIMORE, Aug. 19, 2021 (GLOBE NEWSWIRE) -- Greater Cannabis Company, Inc. (“GCANRx” or the “Company”) (OTCQB: GCAN) a cannabis innovator specializing in the development of pharmaceutical and...
Algernon Logo 1.png
Algernon Pharmaceuticals Announces Exclusive Licensing Agreement with Dartmouth College
August 09, 2021 07:00 ET | Algernon Pharmaceuticals
VANCOUVER, British Columbia, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical...
FStar.jpg
F-star Therapeutics Enters into Exclusive Licensing Agreement with AstraZeneca for Novel STING Inhibitors
July 08, 2021 08:00 ET | F-star Therapeutics, Inc.
CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., July 08, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX) (“F-star” or the “Company”), a clinical-stage biopharmaceutical company...
ArriVent Logo.png
ArriVent Biopharma Launches with Up To $150M in Series A Financing and Strategic Licensing Agreement for Clinical-Stage Oncology Asset
June 30, 2021 07:00 ET | ArriVent Biopharma
Funds will be used to build ArriVent’s portfolio of innovative in-licensed assets for global development Company enters first licensing agreement with Allist Pharma, granting ArriVent ex-China...
logo.jpg
PROCESSA PHARMACEUTICALS ENTERS INTO A LICENSING AGREEMENT WITH OCUPHIRE PHARMA, INC., FOR THE DEVELOPMENT OF RX-3117
June 17, 2021 09:15 ET | Processa Pharmaceuticals, Inc.
HANOVER, MD, June 17, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA) announced today that it has entered into a licensing agreement with Ocuphire Pharma, Inc. (NASDAQ: OCUP)...
Qualcomm 与 LitePoint 签订小型基站产品测试协议
May 05, 2021 21:00 ET | LitePoint
加利福尼亚州圣何塞, May 06, 2021 (GLOBE NEWSWIRE) -- 行业领先的无线测试解决方案提供商 LitePoint 今日宣布与Qualcomm Technologies, Inc.共同签署协议,以支持 LitePoint 开发5G 测试解决方案,用于测试Qualcomm小基站 5G RAN 平台 (FSM 100xx),以加速小基站部署。   5G...
Qualcomm 與 LitePoint 訂定小型基地台產品 測試協議
May 05, 2021 21:00 ET | LitePoint
加州聖荷西, May 06, 2021 (GLOBE NEWSWIRE) -- 業界領先的無線測試解決方案供應商 LitePoint 今日宣布與Qualcomm Technologies, Inc. 共同簽署協議,以支援 LitePoint 開發5G 測試解決方案用於測試 Qualcomm 小型基地台 5G RAN 平台 (FSM 100xx),以加速小型基地台的部署。   5G...